It was suggested that SAMM50 is upregulated in patients with NAFLD, that this upregulation is impaired in the presence of genetic variants in polymorphisms associated with NAFLD and that experimental knock-down of SAMM50 leads to intracellular triglyceride accumulation [18]. This evidence concerns the gene SAMM50 and metabolic dysfunction-associated steatotic liver disease.